Ventyx Biosciences (NASDAQ:VTYX) Shares Gap Down – Time to Sell?

Ventyx Biosciences, Inc. (NASDAQ:VTYX)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $9.38, but opened at $8.88. Ventyx Biosciences shares last traded at $8.7330, with a volume of 921,308 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on VTYX. Canaccord Genuity Group upped their price target on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Wednesday, November 5th. Wall Street Zen upgraded Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Oppenheimer boosted their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Ventyx Biosciences Price Performance

The firm has a market cap of $570.88 million, a PE ratio of -5.33 and a beta of 1.22. The stock has a 50-day moving average price of $6.72 and a 200 day moving average price of $3.95.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13. As a group, equities research analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Hudson Bay Capital Management LP acquired a new position in Ventyx Biosciences in the second quarter valued at $34,000. Persistent Asset Partners Ltd purchased a new position in shares of Ventyx Biosciences in the 3rd quarter worth about $51,000. Pallas Capital Advisors LLC acquired a new position in shares of Ventyx Biosciences in the 2nd quarter valued at about $38,000. Engineers Gate Manager LP acquired a new position in shares of Ventyx Biosciences in the 2nd quarter valued at about $42,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Ventyx Biosciences during the 3rd quarter worth about $61,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.